Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines

Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe autologous virus-targeting vaccines, the powerful immunogenicity of VLPs has been also harnessed to generate immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Ariane C., Flace, Anna, Saudan, Philippe, Zabel, Franziska, Cabral-Miranda, Gustavo, Turabi, Aadil El, Manolova, Vania, Bachmann, Martin F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337491/
https://www.ncbi.nlm.nih.gov/pubmed/28321220
http://dx.doi.org/10.3389/fimmu.2017.00226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337491/
https://www.ncbi.nlm.nih.gov/pubmed/28321220
http://dx.doi.org/10.3389/fimmu.2017.00226

Ejemplares similares